Tru Independence Asset Management 2’s Biogen BIIB Stock Holding History

Tru Independence Asset Management 2’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$432K	Buy	+1,555	New	+$430K	0.43%	45

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tru Independence Asset Management 2's BIIB Position: Q1 2023 in Review

Tru Independence Asset Management 2 opened a new position in Biogen (BIIB) in Q1 2023: 1,555 shares worth $432K. The stake represents 0.43% of the portfolio and ranks #45 among its holdings.

1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

Tru Independence Asset Management 2 held 1,555 shares of Biogen worth $432K as of Q1 2023.
Biogen was a new Tru Independence Asset Management 2 position in Q1 2023.
Biogen made up 0.43% of Tru Independence Asset Management 2's portfolio in Q1 2023, its #45 holding.
1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on Tru Independence Asset Management 2's 13F filing for Q1 2023, filed 26 Apr 2023.